drugset
drugset / Trial / NCT02597036

A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors

NCT02597036 ↗

Phase 1 Terminated 62 enrolled Eli Lilly and Company
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate the safety of the study drug known as LY3127804 given as monotherapy and in combination with Ramucirumab for participants with advanced or metastatic solid tumors. The study will also include a safety exploration for the combination of LY3127804 plus ramucirumab and paclitaxel

Timeline

Start
2015-11-06
Primary completion
2017-11-23
Completion
2020-05-24

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramucirumab Monoclonal antibody 8 mg/kg Intravenous
Subject Ramucirumab Monoclonal antibody 12 mg/kg Intravenous
Subject ZANSECIMAB Monoclonal antibody 4 mg/kg Intravenous
Subject ZANSECIMAB Monoclonal antibody 8 mg/kg Intravenous
Subject ZANSECIMAB Monoclonal antibody 12 mg/kg Intravenous
Subject ZANSECIMAB Monoclonal antibody 16 mg/kg Intravenous
Subject ZANSECIMAB Monoclonal antibody 20 mg/kg Intravenous
Subject ZANSECIMAB Monoclonal antibody 27 mg/kg Intravenous
Background Paclitaxel Small molecule — Intravenous

Indications

cancer